(HealthDay News) — Stockholm3, which combines prostate-specific antigen (PSA), plasma protein biomarkers, polygenic risk, and clinical factors offers greater clinical net benefit for detecting ...

Stockholm3 blood test detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests in a study of over ...

A new study suggests the investigational Stockholm3 blood test may improve the early detection of aggressive prostate cancer ...

For many men, a prostate cancer scare starts with one number. A PSA result comes back high, and ...

A large analysis suggests that a multivariable risk assessment tool, called Stockholm3, can detect substantially more ...

New technologies can potentially save lives by helping identify prostate cancer earlier, and transforming the way doctors ...

“What hurts the most is knowing this didn’t need to be how things turned out,” Diane Adams said of her husband Terry’s death ...

If the US FDA approves it, aglatimagene immunotherapy may become the first new therapy for men with localized prostate cancer in the past 2 decades.

A next-generation Stockholm3 blood test detected aggressive prostate cancer more accurately than PSA, improving early ...

New research suggests that low handgrip strength alone is not a reliable predictor of increased prostate cancer risk among ...